Medivation, Inc. is an American biopharmaceutical company focusing on treatments for cancer.

According to the law firm press release, on August 30, 2016, Montreal, Inc., a wholly-owned subsidiary of Pfizer, commenced a tender offer for Medivation shares scheduled to expire on September 27, 2016. If a sufficient number of Medivation shares are tendered, a second-step merger will be effectuated without a shareholder vote, and Montreal, Inc. will merge with and into Medivation, with Medivation continuing as a wholly-owned subsidiary of Pfizer.

Pursuant to the terms of the Merger Agreement, which was unanimously approved by the Board, Medivation shareholders stand to receive $81.50 per share in cash for each share they own. The Complaint claims that this offer is inadequate in light of the Company's intrinsic value and long-term prospects and alleges that the Schedule 14D-9 Solicitation/Recommendation Statement provides materially incomplete and misleading information about the process leading up to the Board's decision to approve the Proposed Transaction and the valuation analyses performed by the Board's financial advisors, in violation of Sections 14(d)(4), 14(e), and 20(a) of the Exchange Act.

On November 4, 2016, this case was voluntarily dismissed.